A Phase I/Ib Open-label, Multi-center, Dose Escalation Study of GWN323 (Anti-GITR) as a Single Agent and in Combination With PDR001 (Anti-PD-1) in Patients With Advanced Solid Tumors and Lymphomas
Phase of Trial: Phase I
Latest Information Update: 26 Feb 2018
At a glance
- Drugs GWN 323 (Primary) ; Spartalizumab (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
- 17 Nov 2016 Planned End Date changed from 1 Jan 2019 to 1 May 2019.
- 17 Nov 2016 Planned primary completion date changed from 1 Jan 2019 to 1 May 2019.
- 08 Jul 2016 Status changed from not yet recruiting to recruiting.